Study guide

11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

Key Takeaways Explain This Topic AI

Recombinant human growth hormone (somatropin) is dosed in mg/kg/week or mg/m2/week divided into daily evening subcutaneous injections: 0.16–0.24 mg/kg/week for growth hormone deficiency (GHD), and higher doses of 0.35–0.48 mg/kg/week for Turner syndrome, chronic kidney disease (CKD), and small for gestational age (SGA) failing catch-up growth by age 2 to 4 years.

Clinical monitoring for somatropin therapy mandates surveillance for slipped capital femoral epiphysis (SCFE presenting as hip/knee pain and limp), benign intracranial hypertension (pseudotumor cerebri with papilledema and headache), progression of scoliosis, and unmasking of central hypothyroidism.

Classic 21-hydroxylase deficiency (CYP21A2 mutation) causes >90-95% of congenital adrenal hyperplasia (CAH), producing 17-hydroxyprogesterone (17-OHP) accumulation, cortisol and aldosterone deficiency, and adrenal androgen excess, which triggers neonatal salt-wasting crisis (hyponatremia, hyperkalemia, shock, ambiguous genitalia in 46,XX females) between days 7 and 14 of life.

Maintenance pharmacotherapy for classic CAH requires short-acting oral hydrocortisone (8–15 mg/m2/day divided TID; avoiding long-acting dexamethasone/prednisone due to irreversible linear growth stunting), fludrocortisone (0.05–0.2 mg daily), and oral sodium chloride supplementation (1–2 g/day during infancy); physiological stress requires doubling or tripling oral hydrocortisone, or emergency parenteral Solu-Cortef (25–100 mg IV/IM).

Central Precocious Puberty (CPP; onset <8 years in girls, <9 years in boys) is managed with continuous GnRH receptor agonists (Leuprolide acetate depot IM, Triptorelin IM/SC, or the 12-month Histrelin subcutaneous implant) to desensitize pituitary receptors, suppress gonadotropins to prepubertal levels, arrest epiphyseal maturation, and preserve final adult height.

Last updated: September 2026

11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

Pediatric endocrinology encompasses complex hormonal axes that govern linear growth, sexual maturation, and fluid-electrolyte homeostasis. Pharmacotherapy in these conditions requires precise developmental dosing calculations, careful mitigation of growth-stunting drug toxicities, and rapid emergency intervention during acute adrenal decompensation.

Recombinant Human Growth Hormone (Somatropin)

Somatropin is produced by recombinant DNA technology and has an identical 191-amino acid sequence to endogenous pituitary human growth hormone. It stimulates linear bone growth at the epiphyseal growth plates primarily through hepatic and peripheral production of Insulin-like Growth Factor 1 (IGF-1) , while exerting direct anabolic effects on skeletal muscle and lipolytic effects on adipose tissue. Somatropin Clinical Indications & Pediatric Dosing Spectrum:

  • ┌─────────────────────────────┬───────────────────────────┬───────────────────────────────────────┐
  • │ Pediatric Indication │ Dosing (mg/kg/week) │ Clinical Context & Monitoring Pearls │
  • ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
  • │ Growth Hormone Deficiency │ 0.16 to 0.24 mg/kg/week │ Peak GH <10 ng/mL on 2 stim tests; │
  • │ (GHD) │ (0.024–0.034 mg/kg/day) │ highly responsive to lower doses │
  • ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
  • │ Turner Syndrome (45,XO) │ 0.35 to 0.375 mg/kg/week │ SHOX haploinsufficiency; relative GH │
  • │ │ (up to 0.05 mg/kg/day) │ resistance; initiate at age 2–4 yr │
  • ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
  • │ Small for Gestational Age │ 0.35 to 0.48 mg/kg/week │ Birth wt/length <-2 SD failing catch- │
  • │ (SGA failing catch-up) │ (0.05–0.07 mg/kg/day) │ up growth by chronological age 2–4 yr │
  • ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
  • │ Chronic Kidney Disease │ 0.35 mg/kg/week │ Uremic GH resistance; administer │
  • │ (CKD prior to transplant) │ (~0.05 mg/kg/day) │ until renal transplantation occurs │
  • ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
  • │ Prader-Willi Syndrome (PWS) │ 0.24 mg/kg/week │ Screen for sleep apnea/airway obstruc-│
  • │ │ (or 1.0 mg/m2/day) │ tion before initiation (sudden death) │
  • └─────────────────────────────┴───────────────────────────┴───────────────────────────────────────┘
  • Administration & Therapeutic Drug Monitoring

Route & Timing: Administered via daily subcutaneous injections in the evening . Evening dosing mimics the natural physiological nocturnal secretion of growth hormone that occurs during slow-wave deep sleep.

Serum IGF-1 & IGFBP-3 Monitoring: Serum IGF-1 concentrations should be monitored every 6 to 12 months and maintained within the normal age- and sex-adjusted reference range ( -1 to +2 standard deviation scores [SDS] ). Elevated IGF-1 levels (> +2 SDS) mandate dose reduction to prevent acromegalic bone changes and metabolic complications.

Endocrine & Safety Labs:

Thyroid Function: Growth hormone accelerates the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), which may unmask underlying central hypothyroidism . Free T4 and TSH should be checked at baseline and every 6 to 12 months.

Glucose Homeostasis: Somatropin antagonizes insulin signaling and stimulates hepatic gluconeogenesis; fasting glucose and HbA1c should be tracked in children with obesity or family risk of diabetes.

Adverse Effects & Critical Clinical Traps

Benign Intracranial Hypertension (Pseudotumor Cerebri): Typically presents within the first 8 to 12 weeks of initiation with severe morning headaches, nausea, vomiting, diplopia, and bilateral papilledema on fundoscopy. Somatropin must be discontinued immediately . Symptoms typically resolve within days to weeks; therapy may be cautiously re-introduced at a lower dose after complete ophthalmological resolution.

Slipped Capital Femoral Epiphysis (SCFE): Rapid linear growth places mechanical shear stress across the proximal femoral physis, causing posterior and medial displacement of the femoral head. Children present with hip, groin, or referred knee/thigh pain and an antalgic limp . Requires immediate non-weight bearing status and emergent orthopedic surgical evaluation for percutaneous in situ screw pinning.

Progression of Scoliosis: Rapid spinal growth can exacerbate preexisting scoliosis curves; spine surveillance is mandatory.

Prader-Willi Syndrome Airway Mortality: Recombinant GH can induce tonsillar hypertrophy and adenoidal enlargement. A formal polysomnography (sleep study) is mandatory prior to initiation to rule out severe upper airway obstruction; somatropin is contraindicated in severely obese PWS patients or those with severe respiratory impairment.

Congenital Adrenal Hyperplasia (CAH)

Congenital Adrenal Hyperplasia comprises a group of autosomal recessive disorders of adrenal steroidogenesis. Over 90% to 95% of cases are caused by mutations in the CYP21A2 gene encoding the 21-hydroxylase cytochrome P450 enzyme located on chromosome 6p21.3. Adrenal Steroidogenic Pathway in 21-Hydroxylase Deficiency (CAH):

  • Cholesterol
  • │
  • ▼
  • Pregnenolone ─────────────────► 17-OH Pregnenolone ────────► DHEA
  • │ │ │
  • ▼ ▼ ▼
  • Progesterone ─────────────────► 17-OHP Androstenedione
  • │ │ │
  • 21-OHase ───X (BLOCKED!) 21-OHase ───X (BLOCKED!) ▼
  • ▼ ▼ TESTOSTERONE
  • 11-Deoxycorticosterone 11-Deoxycortisol │
  • │ │ ▼
  • ▼ ▼ VIRILIZATION IN UTERO
  • ALDOSTERONE CORTISOL (Ambiguous Genitalia
  • │ │ in 46,XX Females)
  • ▼ ▼
  • SALT-WASTING CRISIS LOSS OF NEGATIVE FEEDBACK
  • (Hyponatremia, Shock, ON PITUITARY ──► MASSIVE
  • Hyperkalemia) ACTH OVERPRODUCTION
  • Pathophysiologic Consequences of 21-Hydroxylase Deficiency

Cortisol Deficiency & Pituitary Overactivation: Deficient cortisol synthesis eliminates normal negative feedback on the hypothalamus and anterior pituitary. The pituitary hypersecretes Adrenocorticotropic Hormone (ACTH) , which drives continuous hyperplasia of the adrenal cortex.

Steroid Precursor Accumulation & Androgen Shunting: The enzymatic block causes massive accumulation of upstream precursors, particularly 17-hydroxyprogesterone (17-OHP) and progesterone. These precursors are shunted into intact adrenal androgen synthesis pathways, generating massive excess of androstenedione and testosterone .

Aldosterone Deficiency: Complete or near-complete lack of 21-hydroxylase impairs mineralocorticoid production, causing renal sodium and water wasting, hypovolemia, and potassium retention.

Clinical Phenotypes & The Neonatal Salt-Wasting Crisis

Classic Salt-Wasting (SW) CAH (~75% of classic cases): Severe enzyme deficiency (<1% activity). Cortisol AND aldosterone are deficient.

In 46,XX Genetic Females: Exposed to massive androgen concentrations in utero, presenting at birth with ambiguous external genitalia (clitoral hypertrophy, labial fusion forming a scrotum-like structure, single urogenital sinus; Prader stages 1–5). Internal reproductive anatomy (uterus, fallopian tubes, ovaries) is completely normal.

In 46,XY Genetic Males: Genitalia appear normal at birth (sometimes subtle scrotal hyperpigmentation). Consequently, affected males escape neonatal visual detection and present between days 7 and 14 of life with life-threatening adrenal salt-wasting crisis .

Triad of Acute Salt-Wasting Crisis:

  • Severe hyponatremia (serum Na < 120–125 mEq/L)
  • Severe hyperkalemia (serum K > 7.0–8.5 mEq/L with peaked T waves and ventricular arrhythmias)
  • Hypovolemic shock, dehydration (>10% weight loss from birth), and metabolic acidosis
  • Frequent hypoglycemia (loss of cortisol counterregulation)

Clinical Trap: Frequently misdiagnosed as septic shock, pyloric stenosis, or congenital cardiac failure.

Diagnostic Confirmation: Newborn dried blood-spot screening demonstrates markedly elevated 17-hydroxyprogesterone (17-OHP) levels (often > 10,000 ng/dL vs. normal < 100–200 ng/dL), confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Pharmacotherapy of Classic CAH Pharmacotherapeutic Regimen for Classic Congenital Adrenal Hyperplasia:

1. GLUCOCORTICOID REPLACEMENT:

  • Drug of Choice: ORAL HYDROCORTISONE (Cortisol)
  • Dose: 8 to 15 mg/m2/day divided THREE TIMES DAILY (TID)
  • Why Hydrocortisone? Short tissue half-life (1.5-2 hr) prevents irreversible growth stunting
  • Avoid Dexamethasone & Prednisone in growing children! (Causes severe growth suppression)
  • Monitoring: Titrated to normalize 17-OHP, androstenedione, and linear growth velocity

2. MINERALOCORTICOID REPLACEMENT:

  • Drug: FLUDROCORTISONE ACETATE (Florinef)
  • Dose: 0.05 to 0.2 mg orally once daily (or divided BID in neonates)
  • Normalizes blood pressure, serum sodium, and suppresses plasma renin activity (PRA)

3. SODIUM CHLORIDE SUPPLEMENTATION (Infancy):

  • Dose: Oral NaCl 1 to 2 g/day (~17 to 34 mEq/day) divided with breast milk / formula feedings
  • Essential during first 12 months because infant diet has low sodium & infant kidneys resist aldosterone

4. STRESS-DOSING RULES (Illness / Surgery):

• Fever (>38.5°C) or moderate illness: DOUBLE or TRIPLE oral hydrocortisone (30-50 mg/m2/day)

  • Emesis, shock, surgery, NPO: Emergency PARENTERAL SOLU-CORTEF IM/IV immediately:
  • Age <3 years: 25 mg IM/IV bolus
  • Age 3-12 years: 50 mg IM/IV bolus
  • Age >12 years: 100 mg IM/IV bolus
  • Why Hydrocortisone is the Exclusive Glucocorticoid of Choice

In pediatric patients with open epiphyses, oral hydrocortisone is the standard of care . It has low glucocorticoid potency (1.0 vs 4.0 for prednisone and 30.0 for dexamethasone) and a short biologic half-life (8 to 12 hours). This short duration minimizes nocturnal suppression of growth hormone release.

Prednisone and Dexamethasone Danger: Synthetic long-acting glucocorticoids have prolonged tissue residence times that cause profound hypothalamic-pituitary suppression, severe linear growth stunting, Cushingoid facies, truncal obesity, osteopenia, and significantly reduced adult height. They are strictly reserved for post-pubertal adolescents who have attained final adult height.

Stress-Dosing Protocols to Prevent Fatal Adrenal Crisis

During systemic illness, fever, or physical trauma, normal physiological cortisol production surges 3- to 5-fold. Children with CAH cannot mount this response:

Mild-to-Moderate Illness (Fever > 38.5°C, gastroenteritis without vomiting): Double or triple the baseline oral hydrocortisone dose ( 30 to 50 mg/m2/day divided TID or QID ). Fludrocortisone dosing remains unchanged.

Severe Stress, Persistent Emesis, Trauma, or General Anesthesia: Families and emergency personnel must immediately administer intramuscular Hydrocortisone sodium succinate (Solu-Cortef) at age-stratified doses (25 mg for <3 yr; 50 mg for 3–12 yr; 100 mg for ≥12 yr) and initiate emergency transport. Intravenous maintenance fluids containing 5% Dextrose in 0.9% Normal Saline (D5 0.9% NaCl) must be infused to correct hypoglycemia and hypovolemia.

Central Precocious Puberty (CPP)

Central Precocious Puberty (CPP, gonadotropin-dependent precocious puberty) is caused by premature, early reactivation of the hypothalamic pulsatile gonadotropin-releasing hormone (GnRH) pulse generator .

Diagnostic Thresholds: Appearance of secondary sexual characteristics before age 8 years in girls (breast bud development [thelarche] or pubarche) and before age 9 years in boys (bilateral testicular enlargement ≥ 4 mL [measured via Prader orchidometer] or pubarche).

Consequences: Premature production of sex steroids (estradiol or testosterone) drives rapid somatic growth velocity accompanied by accelerated skeletal maturation. This causes premature epiphyseal plate fusion , resulting in severe reduction in final adult height (frequently < 5 feet tall), alongside significant psychosocial distress. Mechanism of GnRH Receptor Down-Regulation by GnRH Agonists in CPP:

  • Physiological State: Pulsatile GnRH Secretion (Every 60-90 min)
  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Hypothalamus ──► Pulsatile GnRH ──► Pituitary GnRH Receptors ──► LH & FSH │
  • │ (Promotes normal receptor recycling & continuous pubertal sex steroid surge)│
  • └─────────────────────────────────────────────────────────────────────────────┘
  • │
  • ▼ Continuous Agonist Infusion
  • Therapeutic State: Continuous GnRH Agonist Therapy (Leuprolide, Histrelin)
  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Initial Phase (Days 1–14): Transient "Flare" of LH, FSH, and Sex Steroids │
  • │ │ │
  • │ Chronic Phase (> 2–4 Weeks): RECEPTOR INTERNALIZATION & DESENSITIZATION │
  • │ • Pituitary uncoupling of G-protein signaling │
  • │ • Profound suppression of LH (< 0.3–0.5 IU/L) and FSH │
  • │ • Estradiol (< 10 pg/mL) & Testosterone (< 30 ng/dL) drop to prepubertal │
  • │ • Linear growth velocity normalizes (4–6 cm/yr); bone age maturation stops │
  • │ • Preserves and optimizes final adult height │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Pharmacotherapy with GnRH Agonists

Agent & Formulation Route & Dosing Interval Clinical Administration & Monitoring Pearls

Leuprolide Acetate Depot ( Lupron Depot-Ped ) Intramuscular (IM) ; • Monthly: 7.5 mg (≤25 kg), 11.25 mg (25–37.5 kg), 15 mg (>37.5 kg) q4 weeks; • 3-Month: 11.25 mg or 30 mg q12 weeks; • 6-Month: 45 mg q24 weeks Formulated in biodegradable poly(lactic acid) microspheres. Rotate injection sites. Transient sterile abscess or injection site granuloma occurs in 2–5% of patients.

Triptorelin ( Trelstar / Fensolvi ) IM or SC ; • Trelstar: 3.75 mg IM every 28 days; • Fensolvi: 22.5 mg SC every 6 months Fensolvi uses an in situ polymeric gel depot injected subcutaneously, reducing intramuscular injection pain.

Histrelin Implant ( Supprelin LA ) Subdermal Implant ; • 50 mg implant inserted subdermally into inner upper arm Delivers continuous zero-order release of histrelin (50–65 mcg/day) for 12 full months . Eliminates repeated painful injections and guarantees adherence. Explanted and replaced annually until desired pubertal timing.

Monitoring & Discontinuation Criteria

Suppression Verification: Clinical efficacy is confirmed by measuring GnRH-stimulated peak LH levels (suppressed to < 0.3 to 0.5 IU/L ), prepubertal estradiol (< 10 pg/mL in girls), and prepubertal testosterone (< 30 ng/dL in boys).

Skeletal & Growth Surveillance: Height velocity should decelerate to normal prepubertal rates ( 4 to 6 cm/year ), and bone age progression should stabilize relative to chronological age on annual hand/wrist radiographs.

Discontinuation Timing: Therapy is electively discontinued when the child reaches the chronologically appropriate age for normal puberty (typically age 11 years in girls and age 12 years in boys , or when bone age reaches ~12 to 12.5 years in girls and 13 to 13.5 years in boys). Normal hypothalamic-pituitary-gonadal axis pulsatility resumes within 6 to 12 months after drug cessation, culminating in normal spontaneous puberty, menarche, and future reproductive fertility.